• Vivesto flagged new topline data from its Paccal Vet studies in dogs and cats for presentation at WSAVA World Congress 2026.
• Results were already reported in September 2026; WSAVA presentations run Oct. 13–15 in Warsaw.
• Dog pilot study data supported moving toward a pivotal trial in splenic hemangiosarcoma following splenectomy.
• Cat dose-escalation study showed tolerability with early signs of single-agent anti-tumor activity; final results are expected later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivesto AB published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.